Dr. Angela Smith discusses the recent FDA approval of Jelmyto for low-grade UTUC

Investigators observed promising clinical effect with the EGFR / HER3 bispecific antibody-drug conjugate.

Adam B. Weiner, MD, and Ruchika Talwar, MD, discuss some of the notable urologic oncology abstracts that were presented at the 2023 AUA meeting.

"I think the micronized formulation is something to think about," says Gautam Jayram, MD.

“When you compound the patient delay and…the physician delay, then you really get a delay in diagnosis,” says Curtis A. Pettaway, MD.

Raveen Syan, MD, highlights 2 sessions that she took part in during the 2024 AUA Annual Meeting in San Antonio, Texas on urodynamics in the context of the VALUE trial and the new wave of percutaneous tibial nerve stimulation devices.

"So, there's a lot of evidence to point to the androgen receptor being an important player in at least developing this disease," says Edward M. Messing, MD.